US20230322680A1 - Crystalline forms of pitavastatin calcium - Google Patents
Crystalline forms of pitavastatin calcium Download PDFInfo
- Publication number
- US20230322680A1 US20230322680A1 US18/336,332 US202318336332A US2023322680A1 US 20230322680 A1 US20230322680 A1 US 20230322680A1 US 202318336332 A US202318336332 A US 202318336332A US 2023322680 A1 US2023322680 A1 US 2023322680A1
- Authority
- US
- United States
- Prior art keywords
- characteristic
- powder diffraction
- ray powder
- diffraction pattern
- pitavastatin calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 title abstract description 38
- 229960003296 pitavastatin calcium Drugs 0.000 title description 24
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 30
- YURNCBVQZBJDAJ-AATRIKPKSA-N (E)-hept-2-enoic acid Chemical compound CCCC\C=C\C(O)=O YURNCBVQZBJDAJ-AATRIKPKSA-N 0.000 claims description 11
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000000725 suspension Substances 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- 229960002797 pitavastatin Drugs 0.000 description 8
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 239000012431 aqueous reaction media Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- NBDQGOCGYHMDSJ-NRFPMOEYSA-M sodium;(e,3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound [Na+].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 NBDQGOCGYHMDSJ-NRFPMOEYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RCARMBIYAHBUHR-UQECUQMJSA-N tert-butyl (e,3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)(C)OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RCARMBIYAHBUHR-UQECUQMJSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention is directed to new crystalline forms and the amorphous form of Pitavastatin calcium, processes for the preparation thereof and pharmaceutical compositions comprising these forms.
- the present invention relates to new crystalline forms and the amorphous form of Pitavastatin calcium.
- Pitavastatin is also known by the names NK-104, Itavastatin and Nisvastatin.
- Pitavastatin calcium is known by the chemical name: (3R, 5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt.
- Pitavastatin calcium has the following formula:
- the amorphous form is encountered. Different polymorphs, pseudopolymorphs or the amorphous form differ in their physical properties such as melting point, solubility etc. These can appreciably influence pharmaceutical properties such as dissolution rate and bioavailability. It is also economically desirable that the product is stable for extended periods of time without the need for specialized storage conditions. It is therefore important to evaluate polymorphism of drug substances. Furthermore, the discovery of new crystalline polymorphic forms of a drug enlarge the repertoire of materials that a formulation scientist has with which to design a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristics. We now have surprisingly found novel crystalline forms of Pitavastatin calcium, herein designated as form A, B, C, D, E and F, and the amorphous form of Pitavastatin calcium.
- the present invention is directed to the polymorphic Forms A, B, C, D, E and F, and the amorphous form of Pitavastatin calcium salt (2:1).
- Another object of the invention is a crystalline polymorph of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form B, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values ( ⁇ ) and in 2 ⁇ as given in Table 2.
- Another object of the invention is a crystalline polymorph of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form C, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values ( ⁇ ) and in 2 ⁇ as given in Table 3.
- Another object of the invention is a crystalline polymorph of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form D, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values ( ⁇ ) and in 2 ⁇ as given in Table 4.
- Another object of the invention is a crystalline polymorph of (3R,58)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form E, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values ( ⁇ ) and in 2 ⁇ as given in Table 5.
- Another object of the invention is a crystalline polymorph of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form F, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values ( ⁇ ) and in 2 ⁇ as given in Table 6.
- Another object of the invention is the amorphous form of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt which exhibits characteristic X-ray powder diffraction patterns as depicted in FIG. 7 .
- Powder X-ray diffraction is performed on a Philips 1710 powder X-ray diffractometer using Cu k ( ⁇ 1) radiation (1.54060 ⁇ ); 2 ⁇ angles are recorded with an experimental error of ⁇ 0.1-0.2°.
- a discussion of the theory of X-ray powder diffraction patterns can be found in “X-ray diffraction procedures” by H. P. Klug and L. E. Alexander, J. Wiley, New York (1974).
- the present invention is directed to processes for the preparation of Form B, C, D, E and F, and the amorphous form of Pitavastatin calcium.
- Form A can be generally prepared from Pitavastatin sodium upon reaction with CaCl 2 in an aqueous reaction medium.
- Form A of the invention may also be obtained in situ from the free acid ((3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid) or the corresponding lactone with Ca(OH) 2 , advantageously also in an aqueous reaction medium.
- the aqueous reaction medium usually contains at least 80% b.w. of water; preferably it is water or water containing minor amounts of solvents and/or reactants from previous steps.
- Form A may contain up to 15% water, preferably about 3 to 12%, more preferably 9 to 11% of water.
- Form B can be generally prepared by suspending form A in ethanol containing water as a co solvent.
- the amount of water is preferably about 1 to 50%.
- Form C can be generally prepared by suspending form A in isopropanol containing water as a co solvent.
- the amount of water is preferably about 1 to 50%, especially 1 to 20% and more preferably about 5%.
- Form C can also be prepared from a mixture of isopropanol and a ketone solvent, containing water as a co solvent.
- the ketone solvent is acetone, and the amount of ketone solvent are about 1 to 30%, more preferably about 10%.
- the amount of water is preferably about 1 to 20%, more preferably about 5%.
- Form D can be generally prepared by suspending form A in absolute ethanol.
- Form E can be generally prepared by suspending form A in 1,4-dioxane containing water as a co solvent.
- the amount of water is preferably about 1 to 50%.
- Form F can be generally prepared by suspending form A in methanol containing water as a co solvent.
- the amount of water is preferably about 1 to 50%.
- seeding crystals of the desired crystalline form may be added to the reaction mixture. Preferably small amounts are about 1 to 20 weight %, more preferably about 5 weight %. Seeding crystals may be added before or, where appropriate, after the step initiating the crystallization (e. g. cooling, addition of non-solvent etc. as described above). Addition before initiating the crystallization is of specific technical interest.
- the amorphous form can be generally prepared by addition of a non-solvent to a. concentrated solution of Pitavastatin calcium in an organic solvent.
- non-solvent may be taken for example heptane or methyl tert-butyl ether, whereas examples for the organic solvent are 1,4-dioxane, tetrahydrofuran and ethyl methyl ketone. It is preferable that the non-solvent and solvent are miscible.
- the amorphous form can also be prepared by lyophilization of an aqueous solution of Pitavastatin calciwn.
- Preparations of polymorphic forms A, B, C, D, E, F as well as the amorphous form are usually done in substantially pure reaction systems, essentially consisting of the educt specified, preferably in substantially crystalline form, and solvents and/or non-solvents as given above.
- Another object of the present invention are processes for the preparation of crystalline forms of Pitavastatin calcium essentially free of residual organic solvent.
- the present invention is related to processes for the preparation of crystalline forms of Pitavastatin calcium essentially free of residual organic solvent by exposing the crystalline form of Pitavastatin calcium to an atmosphere with a defined relative air humidity. More particularly, the present invention is directed to a process for the preparation of any crystalline form or amorphous form of Pitavastatin calcium which is essentially free of residual organic solvent.
- These can, for example, be prepared by exposing the crystalline form or amorphous form to an atmosphere with a relative air humidity of 5 to 100%.
- these are prepared by exposure to an inert gas stream with a defined relative air humidity to exchange residual organic solvent with water.
- compositions comprising an effective amount of crystalline polymorphic Form A, B, C, D, E or F or the amorphous form of Pitavastatin calcium, and a pharmaceutical acceptable carrier.
- polymorphic forms may be used as single component or as mixtures with other crystalline forms or the amorphous form.
- novel polymorphic forms and amorphous form of Pitavastatin calcium it is preferred that these contain 25-100% by weight, especially 50-100% by weight, of at least one of the novel forms, based on the total amount of Pitavastatin calcium.
- such an amount of the novel polymorphic forms or amorphous form of Pitavastatin calcium is 75-100% by weight, especially 90-100% by weight. Highly preferred is an amount of 95-100% by weight.
- compositions of the invention include powders, granulates, aggregates and other solid compositions comprising at least one of the novel forms.
- compositions that are contemplated by the present invention may further include diluents, such as cellulose-derived materials like powdered cellulose, microcrystalline cellulose, microfine cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl, cellulose salts and other substituted and unsubstituted celluloses; starch; pregelatinized starch; inorganic diluents like calcium carbonate and calcium diphosphate and other diluents known to the pharmaceutical industry.
- suitable diluents include waxes, sugars and sugar alcohols like mannitol and sorbitol, acrylate polymers and copolymers, as well as pectin, dextrin and gelatin.
- excipients that are within the contemplation of the present invention include binders, such as acacia gum, pregelatinized starch, sodium alginate, glucose and other binders used in wet and dry granulation and direct compression tableting processes.
- binders such as acacia gum, pregelatinized starch, sodium alginate, glucose and other binders used in wet and dry granulation and direct compression tableting processes.
- Excipients that also may be present in the solid compositions further include disintegrants like sodium starch glycolat, crospovidone, low-substituted hydroxypropyl cellulose and others.
- excipients may include tableting lubricants like magnesium and calcium stearate and sodium stearyl furnarate; flavorings; sweeteners; preservatives; pharmaceutically acceptable dyes and glidants such as silicon dioxide.
- the dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration.
- parenteral including subcutaneous, intramuscular, and intravenous
- inhalant and ophthalmic administration are examples of the most suitable route in any given case.
- oral the most preferred route of the present invention is oral.
- the dosages may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
- Dosage forms include solid dosage forms, like tablets, powders, capsules, suppositories, sachets, troches and losenges as well as liquid suspensions and elixirs. While the description is not intended to be limiting, the invention is also not intended to pertain to true solutions of Pitavastatin calcium whereupon the properties that distinguish the solid forms of Pitavastatin calcium are lost. However, the use of the novel forms to prepare such solutions is considered to be within the contemplation of the invention.
- Capsule dosages will contain the solid composition within a capsule which may be made of gelatin or other conventional encapsulating material.
- Tablets and powders may be coated. Tablets and powders may be coated with an enteric coating.
- the enteric coated powder forms may have coatings comprising phthalic acid cellulose acetate, hydroxypropylmethyl-cellulose phthalate, polyvinyl alcohol phthalate, carboxymethylethylcellulose, a copolymer of styrene and maleic acid, a copolymer of methacrylic acid and methyl methacrylate, and like materials, and if desired, they may be employed with suitable plasticizers and/or extending agents.
- a coated tablet may have a coating on the surface of the tablet or may be a tablet comprising a powder or granules with an enteric-coating.
- Preferred unit dosages of the pharmaceutical compositions of this invention typically contain from 0.5 to 100 mg of the novel Pitavastatin calcium forms or mixtures thereof with each other or other fortes of Pitavastatin calcium. More usually, the combined weight of the Pitavastatin calcium forms of a unit dosage are from 2.5 mg to 80 mg, for example 5, 10, 20 or 40 mg.
- the aqueous phase was separated and once extracted with 20 ml of methyl tert-butyl ether. To this aqueous solution were added a solution of 0.58 gr CaCl 2 in 80 ml of water over a period of 1 hour. The resulting suspension was stirred for about 16 hours at room temperature. The suspension was filtered and the obtained solid was dried at 40° C. and 50 mbar for about 16 hours, The obtained product is crystal Form A which is characterized by an X-ray powder diffraction pattern as shown in FIG. 1 . Further characterization of the obtained Form A by thermogravimetry coupled with FT-IR spectroscopy revealed a water content of about 10%. Differential scanning calorimetry revealed a melting point of 95° C.
- FIG. 1 is a characteristic X-ray powder diffraction pattern for Form A.
- FIG. 2 is a characteristic X-ray powder diffraction pattern for Form B.
- FIGS. 3 A and 3 B are two characteristic X-ray powder diffraction patterns for Form C.
- FIG. 4 is a characteristic X-ray powder diffraction pattern for Form D.
- FIG. 5 is a characteristic X-ray powder diffraction pattern for Form E.
- FIG. 6 is a characteristic X-ray powder diffraction pattern for Form F.
- FIGS. 7 A and 7 B are two characteristic X-ray powder diffraction patterns for the amorphous form.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
Description
- This application is a continuation of U.S. Ser. No. 17/675,413, filed Feb. 18, 2022, which is a continuation of U.S. patent application Ser. No. 17/029,692, filed Sep. 23, 2020, which is a continuation of U.S. patent application Ser. No. 16/740,516, filed Jan. 13, 2020, which is a continuation of U.S. patent application Ser. No. 16/400,566, filed May 1, 2019, now abandoned, which is a continuation of U.S. patent application Ser. No. 16/053,879, filed Aug. 3, 2018, now abandoned, which is a continuation of U.S. patent application Ser. No. 15/725,397, filed Oct. 5, 2017, now abandoned, which is a continuation of U.S. patent application Ser. No. 15/284,561, filed Oct. 4, 2016, now abandoned, which is a continuation of U.S. patent application Ser. No. 14/872,255, filed Oct. 1, 2015, now abandoned, which is a continuation of U.S. patent application Ser. No. 14/468,572, filed. Aug. 26, 2014, now abandoned, which is a continuation of U.S. patent application Ser. No. 14/016,399, filed Sep. 3, 2013, now U.S. Pat. No. 8,853,405, which is a continuation of U.S. patent application Ser. No. 13/664,498, filed Oct. 31, 2012, now U.S. Pat. No. 8,557,993, which is a continuation of U.S. patent application Ser. No. 13/280,431, filed Oct. 25, 2011, now abandoned, which is a continuation of U.S. patent application Ser. No. 12/331,086, filed Dec. 9, 2008, now abandoned, which is a continuation of U.S. patent application Ser. No. 10/544,752, filed on Aug. 8, 2005, now abandoned, which was the U.S. National Stage of International Patent Application No. PCT/EP2004/050066, filed Feb. 2, 2004, the disclosures of which are incorporated herein by reference in their entireties. This application claims priority to European Patent Application No. 03405080.7, filed Feb. 12, 2003, the disclosure of which is incorporated herein by reference in its entirety.
- The present invention is directed to new crystalline forms and the amorphous form of Pitavastatin calcium, processes for the preparation thereof and pharmaceutical compositions comprising these forms.
- The present invention relates to new crystalline forms and the amorphous form of Pitavastatin calcium. Pitavastatin is also known by the names NK-104, Itavastatin and Nisvastatin. Pitavastatin calcium is known by the chemical name: (3R, 5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt. Pitavastatin calcium has the following formula:
- Pitavastatin calcium has recently been developed as a new chemically synthesized and powerful statin by Kowa Company Ltd, Japan. On the basis of reported data, the potency of Pitavastatin is dose-dependent and appears to be equivalent to that of Atorvastatin. This new statin is safe and well tolerated in the treatment of patients with hypercholesterolaemia. Significant interactions with a number of other commonly used drugs can be considered to be extremely low.
- Processes for the preparation of Pitavastatin are described in EP-A-0304063 and EP-A-1099694 and in the publications by N. Miyachi et al. in Tetrahedron Letters (1993) vol. 34, pages 8267-8270 and by K. Takahashi et al. in Bull. Chem. Soc. Jpn. (1995) vol. 68, 2649-2656. These publications describe the synthesis of Pitavastatin in great detail but do not describe the hemicalcium salt of Pitavastatin. The publications by L. A. Sorbera et al. in Drugs of the Future (1998) vol. 23, pages 847-859 and by M. Suzuki et al. in Bioorganic & Medicinal Chemistry Letters (1999) vol. 9, pages 2977-2982 describe Pitavastatin calcium, however, a precise procedure for its preparation is not given. A full synthetic procedure for the preparation of Pitavastatin calcium is described in EP-A-0520406. In the process described in this patent Pitavastatin calcium is obtained by precipitation from an aqueous solution as a white crystalline material with a melting point of 190-192 C. It is known that pharmaceutical substances can exhibit polymorphism. Polymorphism is commonly defined as the ability of any substance to have two or more different crystal structures. Drug substances may also encapsulate solvent molecules when crystallized. These solvates or hydrates are referred to as pseudopolymorphs. It is also possible that the amorphous form is encountered. Different polymorphs, pseudopolymorphs or the amorphous form differ in their physical properties such as melting point, solubility etc. These can appreciably influence pharmaceutical properties such as dissolution rate and bioavailability. It is also economically desirable that the product is stable for extended periods of time without the need for specialized storage conditions. It is therefore important to evaluate polymorphism of drug substances. Furthermore, the discovery of new crystalline polymorphic forms of a drug enlarge the repertoire of materials that a formulation scientist has with which to design a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristics. We now have surprisingly found novel crystalline forms of Pitavastatin calcium, herein designated as form A, B, C, D, E and F, and the amorphous form of Pitavastatin calcium.
- Accordingly, the present invention is directed to the polymorphic Forms A, B, C, D, E and F, and the amorphous form of Pitavastatin calcium salt (2:1).
- One object of the invention is a crystalline polymorph of (3R, 5S)-7-12-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6 (E)-heptenoic acid hemicalcium salt, herein designated as Form A, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 1 (vs=very strong intensity, s=strong intensity, m=medium intensity, w=weak intensity, vw=very weak intensity).
-
TABLE 1 d-spacings and 2θ angles for Form A. d-spacing [Å] Angle [2θ] Rel. Intensity 17.6 5.0 s 13.0 6.8 s 9.7 9.1 s 8.8 10.0 w 8.4 10.5 m 8.1 11.0 m 6.7 13.3 vw 6.5 13.7 s 6.3 14.0 w 6.0 14.7 w 5.57 15.9 vw 5.25 16.9 w 5.17 17.1 vw 4.82 18.4 m 4.64 19.1 w 4.27 20.8 vs 4.20 21.1 m 4.10 21.6 m 3.87 22.9 m 3.74 23.7 m 3.67 24.2 s 3.53 25.2 w 3.29 27.1 m 3.02 29.6 vw 2.95 30.2 w 2.63 34.0 w - Another object of the invention is a crystalline polymorph of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form B, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 2.
-
TABLE 2 d-spacings and 2θ angles for Form B. d-spacing [Å] Angle [2θ] Rel. Intensity 19.0 4.6 w 16.6 5.3 vs 14.2 6.2 s 11.5 7.7 s 9.6 9.2 m 9.2 9.6 m 8.5 10.3 w 7.8 11.3 m 7.6 11.7 w 7.0 12.6 vw 6.8 13.0 w 6.4 13.9 m 6.0 14.7 vw 5.94 14.9 w 5.66 15.6 w 5.43 16.3 m 5.22 17.0 vw 5.10 17.4 vw 4.92 18.0 w 4.74 18.7 m 4.59 19.3 m 4.43 20.0 s 4.33 20.5 w 4.26 20.8 m 4.19 21.2 w, shoulder 4.13 21.5 m 3.97 22.4 m 3.83 23.2 s 3.73 23.6 m 3.64 24.4 vw 3.53 25.2 w, broad 3.42 26.0 w 3.37 26.4 vw 3.30 27.0 w 3.19 27.9 vw 3.09 28.9 w - Another object of the invention is a crystalline polymorph of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form C, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 3.
-
TABLE 3 d-spacings and 2θ angles for Form C. d-spacing [Å] Angle [2θ] Rel. Intensity 21.6 4.1 m 15.9 5.6 s 11.4 7.8 m 10.6 8.3 m 8.6 10.3 m 7.7 11.6 w 5.06 17.5 w 4.95 17.9 w 4.74 18.7 m 4.55 19.5 s 4.31 20.6 m 4.13 21.5 vw 4.06 21.9 m 3.84 23.1 m 3.71 24.0 w 3.58 24.8 w - Another object of the invention is a crystalline polymorph of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form D, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 4.
-
TABLE 4 d-spacings and 2θ angles for Form D. d-spacing [Å] Angle [2θ] Rel. Intensity 17.5 5.0 m 13.5 6.5 m 13.0 6.8 s 10.1 8.7 m 8.8 10.0 m 8.6 10.2 m 8.2 10.8 m 6.8 13.1 w 6.55 13.5 m 6.20 14.3 s 5.78 15.3 vw 5.52 16.1 m 5.28 16.8 w 4.87 18.2 w 4.80 18.5 m 4.66 19.0 w 4.46 19.9 m 4.34 20.5 m 4.23 21.0 vs 4.09 21.7 s 3.99 22.3 w 3.80 23.4 m 3.70 24.0 m 3.47 25.6 w 3.40 26.2 m - Another object of the invention is a crystalline polymorph of (3R,58)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form E, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 5.
-
TABLE 5 d-spacings and 2θ angles for Form E. d-spacing [Å] Angle [2θ] Rel. Intensity 20.0 4.4 vw 17.7 5.0 s 13.4 6.6 s 13.1 6.8 s 10.0 8.9 s 8.8 10.0 m 8.6 10.3 s 8.2 10.8 m 6.6 13.3 s 6.5 13.6 m 6.3 14.0 s 5.84 15.2 vw 5.56 15.9 w 5.39 16.4 w 5.24 16.9 vw 4.99 17.8 vw 4.84 18.3 m 4.69 18.9 w 4.39 20.2 vs 4.34 20.4 m 4.30 20.7 m 4.24 20.9 m 4.21 21.1 vs 4.12 21.6 m 4.08 21.7 m 3.99 22.3 m 3.77 23.5 m 3.73 23.8 m 3.69 24.1 w 3.60 24.7 vw 3.50 25.4 vw 3.35 26.6 m 2.96 30.2 w 2.64 34.0 vw - Another object of the invention is a crystalline polymorph of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt, herein designated as Form F, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 6.
-
TABLE 6 d-spacing and 2θ angles for Form F. d-spacing [Å] Angle [2θ] Rel. Intensity 17.2 5.1 m 15.8 5.6 w 12.6 7.0 s 10.0 8.8 m 9.2 9.6 s 8.7 10.2 w 8.1 10.9 m 7.8 11.3 w 7.4 11.9 m 7.1 12.5 m 6.8 13.0 s 6.5 13.7 m 6.2 14.4 s 8.04 14.7 m 5.79 15.3 vw 5.70 15.5 w 5.28 16.8 m 5.03 17.6 w 4.85 18.3 m 4.61 19.3 m 4.51 19.7 m 4.30 20.6 m 4.18 21.2 vs 4.08 21.8 s 3.90 22.8 s 3.84 23.1 w 3.74 23.8 w, shoulder 3.69 24.1 s 3.59 24.8 s 3.46 25.7 m 3.40 26.2 vw 3.35 26.6 m 3.31 26.9 w 3.14 28.4 w 3.02 29.5 w 3.00 29.8 vw 2.89 30.9 m - Small changes in the experimental details can cause small deviation in the d-values and 2θ of characteristic peaks in the X-ray powder diffraction patterns.
- Another object of the invention is the amorphous form of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt which exhibits characteristic X-ray powder diffraction patterns as depicted in
FIG. 7 . - Powder X-ray diffraction is performed on a Philips 1710 powder X-ray diffractometer using Cu k (α1) radiation (1.54060 Å); 2θ angles are recorded with an experimental error of ±0.1-0.2°. A discussion of the theory of X-ray powder diffraction patterns can be found in “X-ray diffraction procedures” by H. P. Klug and L. E. Alexander, J. Wiley, New York (1974).
- Furthermore, the present invention is directed to processes for the preparation of Form B, C, D, E and F, and the amorphous form of Pitavastatin calcium.
- Form A can be generally prepared from Pitavastatin sodium upon reaction with CaCl2 in an aqueous reaction medium. Alternatively, Form A of the invention may also be obtained in situ from the free acid ((3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid) or the corresponding lactone with Ca(OH)2, advantageously also in an aqueous reaction medium. The aqueous reaction medium usually contains at least 80% b.w. of water; preferably it is water or water containing minor amounts of solvents and/or reactants from previous steps. Form A may contain up to 15% water, preferably about 3 to 12%, more preferably 9 to 11% of water.
- Form B can be generally prepared by suspending form A in ethanol containing water as a co solvent. The amount of water is preferably about 1 to 50%.
- Form C can be generally prepared by suspending form A in isopropanol containing water as a co solvent. The amount of water is preferably about 1 to 50%, especially 1 to 20% and more preferably about 5%. Form C can also be prepared from a mixture of isopropanol and a ketone solvent, containing water as a co solvent. Preferably, the ketone solvent is acetone, and the amount of ketone solvent are about 1 to 30%, more preferably about 10%. The amount of water is preferably about 1 to 20%, more preferably about 5%.
- Form D can be generally prepared by suspending form A in absolute ethanol.
- Form E can be generally prepared by suspending form A in 1,4-dioxane containing water as a co solvent. The amount of water is preferably about 1 to 50%.
- Form F can be generally prepared by suspending form A in methanol containing water as a co solvent. The amount of water is preferably about 1 to 50%.
- In the above mentioned processes small amounts of seeding crystals of the desired crystalline form may be added to the reaction mixture. Preferably small amounts are about 1 to 20 weight %, more preferably about 5 weight %. Seeding crystals may be added before or, where appropriate, after the step initiating the crystallization (e. g. cooling, addition of non-solvent etc. as described above). Addition before initiating the crystallization is of specific technical interest.
- The amorphous form can be generally prepared by addition of a non-solvent to a. concentrated solution of Pitavastatin calcium in an organic solvent. As non-solvent may be taken for example heptane or methyl tert-butyl ether, whereas examples for the organic solvent are 1,4-dioxane, tetrahydrofuran and ethyl methyl ketone. It is preferable that the non-solvent and solvent are miscible. The amorphous form can also be prepared by lyophilization of an aqueous solution of Pitavastatin calciwn.
- Preparations of polymorphic forms A, B, C, D, E, F as well as the amorphous form are usually done in substantially pure reaction systems, essentially consisting of the educt specified, preferably in substantially crystalline form, and solvents and/or non-solvents as given above.
- Another object of the present invention are processes for the preparation of crystalline forms of Pitavastatin calcium essentially free of residual organic solvent.
- Particularly, the present invention is related to processes for the preparation of crystalline forms of Pitavastatin calcium essentially free of residual organic solvent by exposing the crystalline form of Pitavastatin calcium to an atmosphere with a defined relative air humidity. More particularly, the present invention is directed to a process for the preparation of any crystalline form or amorphous form of Pitavastatin calcium which is essentially free of residual organic solvent. These can, for example, be prepared by exposing the crystalline form or amorphous form to an atmosphere with a relative air humidity of 5 to 100%. Preferably, these are prepared by exposure to an inert gas stream with a defined relative air humidity to exchange residual organic solvent with water. In general, a relative air humidity of 5 to 100%, especially 40 to 80%, is used.
- Another object of the present invention are pharmaceutical compositions comprising an effective amount of crystalline polymorphic Form A, B, C, D, E or F or the amorphous form of Pitavastatin calcium, and a pharmaceutical acceptable carrier.
- These polymorphic forms may be used as single component or as mixtures with other crystalline forms or the amorphous form.
- As to the novel polymorphic forms and amorphous form of Pitavastatin calcium it is preferred that these contain 25-100% by weight, especially 50-100% by weight, of at least one of the novel forms, based on the total amount of Pitavastatin calcium. Preferably, such an amount of the novel polymorphic forms or amorphous form of Pitavastatin calcium is 75-100% by weight, especially 90-100% by weight. Highly preferred is an amount of 95-100% by weight.
- The compositions of the invention include powders, granulates, aggregates and other solid compositions comprising at least one of the novel forms. In addition, the compositions that are contemplated by the present invention may further include diluents, such as cellulose-derived materials like powdered cellulose, microcrystalline cellulose, microfine cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl, cellulose salts and other substituted and unsubstituted celluloses; starch; pregelatinized starch; inorganic diluents like calcium carbonate and calcium diphosphate and other diluents known to the pharmaceutical industry. Yet other suitable diluents include waxes, sugars and sugar alcohols like mannitol and sorbitol, acrylate polymers and copolymers, as well as pectin, dextrin and gelatin.
- Further excipients that are within the contemplation of the present invention include binders, such as acacia gum, pregelatinized starch, sodium alginate, glucose and other binders used in wet and dry granulation and direct compression tableting processes. Excipients that also may be present in the solid compositions further include disintegrants like sodium starch glycolat, crospovidone, low-substituted hydroxypropyl cellulose and others. In addition, excipients may include tableting lubricants like magnesium and calcium stearate and sodium stearyl furnarate; flavorings; sweeteners; preservatives; pharmaceutically acceptable dyes and glidants such as silicon dioxide.
- The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable route in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
- Dosage forms include solid dosage forms, like tablets, powders, capsules, suppositories, sachets, troches and losenges as well as liquid suspensions and elixirs. While the description is not intended to be limiting, the invention is also not intended to pertain to true solutions of Pitavastatin calcium whereupon the properties that distinguish the solid forms of Pitavastatin calcium are lost. However, the use of the novel forms to prepare such solutions is considered to be within the contemplation of the invention.
- Capsule dosages, of course, will contain the solid composition within a capsule which may be made of gelatin or other conventional encapsulating material. Tablets and powders may be coated. Tablets and powders may be coated with an enteric coating. The enteric coated powder forms may have coatings comprising phthalic acid cellulose acetate, hydroxypropylmethyl-cellulose phthalate, polyvinyl alcohol phthalate, carboxymethylethylcellulose, a copolymer of styrene and maleic acid, a copolymer of methacrylic acid and methyl methacrylate, and like materials, and if desired, they may be employed with suitable plasticizers and/or extending agents. A coated tablet may have a coating on the surface of the tablet or may be a tablet comprising a powder or granules with an enteric-coating.
- Preferred unit dosages of the pharmaceutical compositions of this invention typically contain from 0.5 to 100 mg of the novel Pitavastatin calcium forms or mixtures thereof with each other or other fortes of Pitavastatin calcium. More usually, the combined weight of the Pitavastatin calcium forms of a unit dosage are from 2.5 mg to 80 mg, for example 5, 10, 20 or 40 mg.
- The following Examples illustrate the invention in more detail. Temperatures are given in degrees Celsius.
- 4.15 gr of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid tert-butyl ester (Pitavastatin tert-butyl ester) was suspended in 52 ml of a mixture of methyl tert-butyl ether and methanol (10:3). To this mixture were added 2.17 ml of a 4M aqueous solution of NaOH, and the resulting yellowish solution was stirred for 2.5 hours at 50° C. The reaction mixture was cooled to room temperature followed by the addition of 50 ml water and stirring for an additional hour. The aqueous phase was separated and once extracted with 20 ml of methyl tert-butyl ether. To this aqueous solution were added a solution of 0.58 gr CaCl2 in 80 ml of water over a period of 1 hour. The resulting suspension was stirred for about 16 hours at room temperature. The suspension was filtered and the obtained solid was dried at 40° C. and 50 mbar for about 16 hours, The obtained product is crystal Form A which is characterized by an X-ray powder diffraction pattern as shown in
FIG. 1 . Further characterization of the obtained Form A by thermogravimetry coupled with FT-IR spectroscopy revealed a water content of about 10%. Differential scanning calorimetry revealed a melting point of 95° C. - 100 mg Pitavastatin calcium Form A was suspended in 2 ml water and stirred at room temperature for 30 min, followed by the addition of 2 ml of ethanol and additional stirring for 18 hours. The suspension was filtered and dried in air, yielding 36 mg of Form B. The obtained crystal Form B is characterized by an X-ray powder diffraction pattern as shown in
FIG. 2 . Further characterization of the obtained Form B by thermogravimetry coupled with FT-IR spectroscopy revealed a water content of about 10%. - 62 mg Pitavastatin calcium Form A was suspended in 2 ml isopropanol containing 5% water. This suspension was heated to 60° C., which led to almost complete dissolution of Form A, and again cooled to room temperature. At this temperature the suspension was stirred for 66 hours. The resulting suspension was filtered, once washed with some isopropanol containing 5% water, and dried in air. The obtained crystal Form C is characterized by an X-ray powder diffraction pattern as shown in
FIG. 3 . Further characterization of the obtained Form C by thermogravimetry coupled with FT-IR spectroscopy revealed that the sample contains about 6.3% isopropanol and a small amount of water. - 65 mg Pitavastatin calcium Form A was suspended in a mixture of 0.9 ml isopropanol, 0.1 ml acetone and 40 μl water. Stirring this suspension for about 1 hour led to nearly complete dissolution. Seeding with 4 mg of Form C (from example 3) and stirring for 2 hours led to the formation of a concentrated suspension. This suspension was diluted with the same amount of solvent mixture as above and stirred for an additional 40 hours. The suspension was filtered and the obtained solid was dried at 40° C. for about 10 min. Analysis by X-ray powder diffraction indicates the product to be crystal Form C as shown in
FIG. 3 . - 60 mg of Pitavastatin calcium Form A was suspended in 1 ml absolute ethanol and stirred at room temperature for 20 hours. The resulting suspension was filtered and dried in air. The obtained crystal Form D is characterized by an X-ray powder diffraction pattern as shown in
FIG. 4 . - 60 mg of Pitavastatin calcium Form A was suspended in a mixture of 1,4-dioxane and water (1:1), and stirred for 18 hours at room temperature. The resulting suspension was filtered and dried in air. The obtained crystal Form E is characterized by an X-ray powder diffraction pattern as shown in
FIG. 5 . - 60 mg of Pitavastatin calcium Form A was suspended in 3 ml methanol containing 20% water, and stirred at 40° C. for 1 hour. The resulting suspension was slowly cooled to room temperature and stirring was continued for 4 hours. The suspension was heated again to 40° C., stirred for 30 min, slowly cooled to room temperature and stirred for an additionally 15 hours. The suspension was filtered and the obtained white solid dried in air. The obtained crystal Form F is characterized by an X-ray powder diffraction pattern as shown in
FIG. 6 . - 62 mg of Pitavastatin calcium Form A was dissolved in 0.3 ml 1,4-dioxane. To this stirred solution was slowly added 2.3 ml n-heptane at room temperature, and stirred for an additional 16 hours. The resulting suspension was filtered and dried in air. The obtained solid was amorphous as is shown by the X-ray diffraction pattern given in
FIG. 7 (top). - 60 mg of Pitavastatin calcium Form A was dissolved in 1.5 ml ethyl methyl ketone. To this solution was added in steps of 1 ml each 30 sec a total of 21 ml methyl Cert-butyl ether. The resulting suspension was stirred at room temperature for about 16 hours. The suspension was filtered and the obtained solid was dried in air. An X-ray diffraction study on the product showed it to be amorphous, see
FIG. 7 (bottom). Further characterization of the obtained product by thermogravimetry coupled with FT-IR spectroscopy revealed that the sample contained about 5.5% methyl tert-butyl ether. Differential scanning calorimetry showed the sample to have a glass transition temperature of about 68° C. -
FIG. 1 is a characteristic X-ray powder diffraction pattern for Form A. -
FIG. 2 is a characteristic X-ray powder diffraction pattern for Form B. -
FIGS. 3A and 3B are two characteristic X-ray powder diffraction patterns for Form C. -
FIG. 4 is a characteristic X-ray powder diffraction pattern for Form D. -
FIG. 5 is a characteristic X-ray powder diffraction pattern for Form E. -
FIG. 6 is a characteristic X-ray powder diffraction pattern for Form F. -
FIGS. 7A and 7B are two characteristic X-ray powder diffraction patterns for the amorphous form.
Claims (1)
1. A crystalline polymorph A, B, C, D, E, F, or the amorphous form, of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxy-6(E)-heptenoic acid hemicalcium salt wherein
A) polymorph A exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in 22 at 5.0 (s), 6.8 (s), 9.1 (s), 10.0 (w), 10.5 (m), 11.0 (m), 13.3 (vw), 13.7 (s), 14.0 (w), 14.7 (w), 15.9 (vw), 16.9 (w), 17.1 (vw), 18.4 (m), 19.1 (w), 20.8 (vs), 21.1 (m), 21.6 (m), 22.9 (m), 23.7 (m), 24.2 (s), 25.2 (w), 27.1 (m), 29.6 (vw), 30.2 (w), 34.0 (w);
B) polymorph B exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in 22 at 4.6 (w), 5.3 (vs), 6.2 (s), 7.7 (s), 9.2 (m), 9.6 (m), 10.3 (w), 11.3 (m), 11.7 (w), 12.6 (vw), 13.0 (w), 13.9 (m), 14.7 (vw), 14.9 (w), 15.6 (w), 16.3 (m), 17.0 (vw), 17.4 (vw), 18.0 (w), 18.7 (m), 19.3 (m), 20.0 (s), 20.5 (w), 20.8 (m), 21.2 (w, shoulder), 21.5 (m), 22.4 (m), 23.2 (s), 2.,8 (m), 24.4 (vw), 25.2 (w, broad), 26.0 (w), 26.4 (vw), 27.0 (w), 27.9 (vw), 28.9 (w);
C) polymorph C exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in 22 at 4.1 (m), 5.6 (s), 7.8 (m), 8.3 (m), 10.3 (m), 11.6 (w), 17.5 (w), 17.9 (w), 18.7 (m), 19.5 (s), 20.6 (m), 21.5 (vw), 21.9 (m), 23.1 (m), 24.0 (w), 24.8 (w);
D) polymorph D exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in 22 at 5.0 (m), 6.5 (m), 6.8 (s), 8.7 (m), 10.0 (m), 10.2 (m), 10.8 (m), 13.1 (w), 13,5 (m), 14.3 (s), 15.3 (vw), 16.1 (m), 16.8 (w), 18.2 (w), 18.5 (m), 19,0 (w), 19.9 (m), 20.5 (m), 21.0 (vs), 21.7 (s), 22.3 (w), 23.4 (m), 24.0 (m), 25.6 (w), 26.2 (m);
E) polymorph E exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in 22 at 4.4 (vw), 5.0 (s), 6.6 (s), 6.8 (s), 8.9 (s), 10.0 (m), 10.3 (s), 10.8 (m), 13.3 (s), 13.6 (m), 14.0 (s), 15.2 (vw), 15.9 (w), 16.4 (w), 16.9 (vw), 17.8 (vw), 18.3 (m), 18.9 (w), 20.2 (vs), 20.4 (m), 20.7 (m), 20.9 (m), 21.1 (vs), 21.6 (m), 21.7 (m), 22.3 (m), 23.5 (m), 23.8 (m), 24.1 (w), 24.7 (vw), 25.4 (vw), 26.6 (m), 30.2 (w), 34.0 (vw); and
F) polymorph F exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in 22 at 5.1 (m), 5.6 (w), 7.0 (s), 8.8 (m), 9.6 (s), 10.2 (w), 10.9 (m), 11.3 (w), 11.9 (m), 12.5 (m), 13.0 (s), 13.7 (m), 14.4 (s), 14.7 (m), 15.3 (vw), 15.5 (w), 16.8 (m), 17.6 (w), 18.3 (m), 19.3 (m), 19.7 (m), 20.6 (m), 21.2 (vs), 21.8 (s), 22.8 (s), 23.1 (w), 23.8 (w, shoulder), 24.1 (s), 24.8 (s), 25.7 (m), 26.2 (vw), 26.6 (m), 26.9 (w), 28.4 (w), 29.5 (w), 29.8 (vw), 30.9 (m); wherein, for each of said polymorphs, (vs) stands for very strong intensity; (s) stands for strong intensity; (m) stands for medium intensity; (w) stands for weak intensity; (vw) stands for very weak intensity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/336,332 US20230322680A1 (en) | 2003-02-12 | 2023-06-16 | Crystalline forms of pitavastatin calcium |
Applications Claiming Priority (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03405080.7 | 2003-02-12 | ||
EP03405080 | 2003-02-12 | ||
US10/544,752 US20060142582A1 (en) | 2003-02-12 | 2004-02-02 | Crystalline forms of pitavastatin calcium |
PCT/EP2004/050066 WO2004072040A1 (en) | 2003-02-12 | 2004-02-02 | Crystalline forms of pitavastatin calcium |
US12/331,066 US20090084929A1 (en) | 2006-06-12 | 2008-12-09 | Machine Stand |
US13/280,431 US20120101126A1 (en) | 2003-02-12 | 2011-10-25 | Crystalline forms of pitavastatin calcium |
US13/664,498 US8557993B2 (en) | 2003-02-12 | 2012-10-31 | Crystalline forms of pitavastatin calcium |
US14/016,399 US8853405B2 (en) | 2003-02-12 | 2013-09-03 | Crystalline forms of pitavastatin calcium |
US14/468,572 US20140364614A1 (en) | 2003-02-12 | 2014-08-26 | Crystalline forms of pitavastatin calcium |
US14/872,255 US20160024010A1 (en) | 2003-02-12 | 2015-10-01 | Crystalline forms of pitavastatin calcium |
US15/284,561 US20170022163A1 (en) | 2003-02-12 | 2016-10-04 | Crystalline forms of pitavastatin calcium |
US15/725,397 US20180029987A1 (en) | 2003-02-12 | 2017-10-05 | Crystalline forms of pitavastatin calcium |
US16/053,879 US20180346425A1 (en) | 2003-02-12 | 2018-08-03 | Crystalline forms of pitavastatin calcium |
US16/400,566 US20190256469A1 (en) | 2003-02-12 | 2019-05-01 | Crystalline forms of pitavastatin calcium |
US16/740,516 US20200148644A1 (en) | 2003-02-12 | 2020-01-13 | Crystalline forms of pitavastatin calcium |
US17/029,692 US20210002227A1 (en) | 2003-02-12 | 2020-09-23 | Crystalline forms of pitavastatin calcium |
US17/675,413 US20220169614A1 (en) | 2003-02-12 | 2022-02-18 | Crystalline forms of pitavastatin calcium |
US18/336,332 US20230322680A1 (en) | 2003-02-12 | 2023-06-16 | Crystalline forms of pitavastatin calcium |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/675,413 Continuation US20220169614A1 (en) | 2003-02-12 | 2022-02-18 | Crystalline forms of pitavastatin calcium |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230322680A1 true US20230322680A1 (en) | 2023-10-12 |
Family
ID=32865094
Family Applications (15)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/544,752 Abandoned US20060142582A1 (en) | 2003-02-12 | 2004-02-02 | Crystalline forms of pitavastatin calcium |
US12/331,086 Abandoned US20090182008A1 (en) | 2003-02-12 | 2008-12-09 | Crystalline forms of pitavastatin calcium |
US13/280,431 Abandoned US20120101126A1 (en) | 2003-02-12 | 2011-10-25 | Crystalline forms of pitavastatin calcium |
US13/664,498 Expired - Lifetime US8557993B2 (en) | 2003-02-12 | 2012-10-31 | Crystalline forms of pitavastatin calcium |
US14/016,399 Expired - Lifetime US8853405B2 (en) | 2003-02-12 | 2013-09-03 | Crystalline forms of pitavastatin calcium |
US14/468,572 Abandoned US20140364614A1 (en) | 2003-02-12 | 2014-08-26 | Crystalline forms of pitavastatin calcium |
US14/872,255 Abandoned US20160024010A1 (en) | 2003-02-12 | 2015-10-01 | Crystalline forms of pitavastatin calcium |
US15/284,561 Abandoned US20170022163A1 (en) | 2003-02-12 | 2016-10-04 | Crystalline forms of pitavastatin calcium |
US15/725,397 Abandoned US20180029987A1 (en) | 2003-02-12 | 2017-10-05 | Crystalline forms of pitavastatin calcium |
US16/053,879 Abandoned US20180346425A1 (en) | 2003-02-12 | 2018-08-03 | Crystalline forms of pitavastatin calcium |
US16/400,566 Abandoned US20190256469A1 (en) | 2003-02-12 | 2019-05-01 | Crystalline forms of pitavastatin calcium |
US16/740,516 Abandoned US20200148644A1 (en) | 2003-02-12 | 2020-01-13 | Crystalline forms of pitavastatin calcium |
US17/029,692 Abandoned US20210002227A1 (en) | 2003-02-12 | 2020-09-23 | Crystalline forms of pitavastatin calcium |
US17/675,413 Abandoned US20220169614A1 (en) | 2003-02-12 | 2022-02-18 | Crystalline forms of pitavastatin calcium |
US18/336,332 Abandoned US20230322680A1 (en) | 2003-02-12 | 2023-06-16 | Crystalline forms of pitavastatin calcium |
Family Applications Before (14)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/544,752 Abandoned US20060142582A1 (en) | 2003-02-12 | 2004-02-02 | Crystalline forms of pitavastatin calcium |
US12/331,086 Abandoned US20090182008A1 (en) | 2003-02-12 | 2008-12-09 | Crystalline forms of pitavastatin calcium |
US13/280,431 Abandoned US20120101126A1 (en) | 2003-02-12 | 2011-10-25 | Crystalline forms of pitavastatin calcium |
US13/664,498 Expired - Lifetime US8557993B2 (en) | 2003-02-12 | 2012-10-31 | Crystalline forms of pitavastatin calcium |
US14/016,399 Expired - Lifetime US8853405B2 (en) | 2003-02-12 | 2013-09-03 | Crystalline forms of pitavastatin calcium |
US14/468,572 Abandoned US20140364614A1 (en) | 2003-02-12 | 2014-08-26 | Crystalline forms of pitavastatin calcium |
US14/872,255 Abandoned US20160024010A1 (en) | 2003-02-12 | 2015-10-01 | Crystalline forms of pitavastatin calcium |
US15/284,561 Abandoned US20170022163A1 (en) | 2003-02-12 | 2016-10-04 | Crystalline forms of pitavastatin calcium |
US15/725,397 Abandoned US20180029987A1 (en) | 2003-02-12 | 2017-10-05 | Crystalline forms of pitavastatin calcium |
US16/053,879 Abandoned US20180346425A1 (en) | 2003-02-12 | 2018-08-03 | Crystalline forms of pitavastatin calcium |
US16/400,566 Abandoned US20190256469A1 (en) | 2003-02-12 | 2019-05-01 | Crystalline forms of pitavastatin calcium |
US16/740,516 Abandoned US20200148644A1 (en) | 2003-02-12 | 2020-01-13 | Crystalline forms of pitavastatin calcium |
US17/029,692 Abandoned US20210002227A1 (en) | 2003-02-12 | 2020-09-23 | Crystalline forms of pitavastatin calcium |
US17/675,413 Abandoned US20220169614A1 (en) | 2003-02-12 | 2022-02-18 | Crystalline forms of pitavastatin calcium |
Country Status (10)
Country | Link |
---|---|
US (15) | US20060142582A1 (en) |
EP (3) | EP2500339A1 (en) |
JP (13) | JP5192147B2 (en) |
CN (3) | CN102285916B (en) |
AU (1) | AU2004212160B2 (en) |
CA (2) | CA2513837A1 (en) |
DE (1) | DE202004021379U1 (en) |
PL (1) | PL376557A1 (en) |
TW (4) | TWI485135B (en) |
WO (1) | WO2004072040A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL376557A1 (en) * | 2003-02-12 | 2006-01-09 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of pitavastatin calcium |
TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
AU2013204129C1 (en) * | 2003-12-26 | 2017-03-02 | Nissan Chemical Industries, Ltd. | Crystal Form of Quinoline Compound and Process for its Production |
EP1711493A2 (en) * | 2004-02-06 | 2006-10-18 | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement | Crystalline forms of zolmitriptan |
US7932387B2 (en) * | 2005-01-31 | 2011-04-26 | Basf Se | Crystalline forms of rosuvastatin calcium salt |
US20120022102A1 (en) | 2010-01-20 | 2012-01-26 | Cadila Healthcare Limited | Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof |
US9034901B2 (en) | 2010-08-25 | 2015-05-19 | Cadila Healthcare Limited | Pitavastatin calcium and process for its preparation |
US8912333B2 (en) | 2010-11-12 | 2014-12-16 | Hetero Research Foundation | Polymorphs of pitavastatin calcium |
WO2012106584A2 (en) * | 2011-02-04 | 2012-08-09 | Dr. Reddy's Laboratories Ltd. | Pitavastatin salts |
ITMI20111475A1 (en) * | 2011-08-02 | 2013-02-03 | Dipharma Francis Srl | CRYSTALLINE FORMS OF PITAVASTATINE CALCIUM SALT |
PT2751081T (en) | 2011-09-12 | 2017-04-04 | D O O Farma Grs | Polymorphic form of pitavastatin calcium |
AU2012324803B9 (en) * | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
WO2013098773A1 (en) * | 2011-12-28 | 2013-07-04 | Dr. Reddy's Laboratories Limited | Crystalline forms of pitavastatin calcium |
CN104844506A (en) * | 2015-05-15 | 2015-08-19 | 苗怡文 | Medicinal pitavastatin calcium compound for treating hyperlipidemia |
CN104860882A (en) * | 2015-05-15 | 2015-08-26 | 苗怡文 | Drug pitavastatin calcium composition for treating hyperlipidemia |
CN105125504A (en) * | 2015-09-17 | 2015-12-09 | 青岛华之草医药科技有限公司 | Composition granules of blood lipid-lowering drug pitavastatin calcium |
CN105213319A (en) * | 2015-09-17 | 2016-01-06 | 青岛华之草医药科技有限公司 | A kind of blood lipid-lowering medicine Pitavastatin calcium composition dry suspension |
US10937978B2 (en) * | 2016-02-25 | 2021-03-02 | University Of Louisville Research Foundation, Inc. | Methods for forming a perovskite solar cell |
US10600502B2 (en) | 2016-12-20 | 2020-03-24 | Astrazeneca Uk Ltd. | Systems and methods for dispensing a statin medication over the counter |
CN109053568A (en) * | 2018-08-29 | 2018-12-21 | 南京卓康医药科技有限公司 | A kind of high-purity Pitavastatin Calcium novel crystal forms and preparation method thereof |
CN113834795A (en) * | 2020-06-08 | 2021-12-24 | 上海医药集团股份有限公司 | Hydroxychloroquine sulfate particle moisture near infrared spectrum online quantitative model and establishing method and detection method thereof |
US20220008519A1 (en) | 2020-07-09 | 2022-01-13 | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) | Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho |
AU2022350669A1 (en) * | 2021-09-23 | 2024-04-04 | Fritz Blatter | Egfr inhibitor polymorph forms |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557993B2 (en) * | 2003-02-12 | 2013-10-15 | Nissan Chemical Industries Ltd. | Crystalline forms of pitavastatin calcium |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3175944A (en) * | 1956-06-18 | 1965-03-30 | Upjohn Co | Dihydronovobiocin and derivatives thereof |
JPS61171460A (en) | 1985-01-23 | 1986-08-02 | Dainippon Pharmaceut Co Ltd | Production of i-type crystal of meclofenoxate hydrochloride |
CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
JP2569746B2 (en) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | Quinoline mevalonolactones |
GB8816620D0 (en) * | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
JP3528186B2 (en) | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | Diastereomeric salts of optically active quinoline mevalonic acid |
DE69318077T2 (en) | 1992-07-31 | 1998-10-29 | Shionogi & Co | Triazolylthiomethylthiocephalosporin hydrochloride, its crystalline hydrate and its preparation |
JP2575590B2 (en) | 1992-07-31 | 1997-01-29 | 塩野義製薬株式会社 | Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation |
GB9324931D0 (en) * | 1993-12-04 | 1994-01-26 | Pfizer Ltd | Glutaramide derivatives |
WO1995023125A1 (en) | 1994-02-25 | 1995-08-31 | Daicel Chemical Industries, Ltd. | Process for producing optically active mevalonolactone compound |
JP3558684B2 (en) | 1994-06-28 | 2004-08-25 | 塩野義製薬株式会社 | Method for drying pyrrolidylthiocarbapenem derivative |
PT1099694E (en) | 1998-07-23 | 2005-10-31 | Nissan Chemical Ind Ltd | PROCESS FOR THE PREPARATION OF A QUINOLINE DERIVATIVE AND AN INTERMEDIARY FOR THAT END |
JP4749533B2 (en) * | 1999-09-30 | 2011-08-17 | 大塚化学株式会社 | Cephalosporin crystal |
CA2426393C (en) * | 2000-10-31 | 2012-05-29 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of venlafaxine hydrochloride |
ES2313999T3 (en) * | 2000-11-16 | 2009-03-16 | Teva Pharmaceutical Industries Ltd. | STERE HYDROLYSIS OF ACID (R (R *, R *)) - 2- (4-FLUOROPHENIL) -BETA, DELTA-DIHIDROXI-5- (1-METHYLETY) -3-PHENYL-4 - ((PHENYLAMINE) CARBON) -1H-PIRROL-1-HEPTANOIC WITH CALCICO HYDROXIDE. |
US20040063961A1 (en) * | 2000-12-21 | 2004-04-01 | Van Der Schaaf Paul Adriaan | Crystalline forms of cerivastatin sodium |
AU2002324715B2 (en) * | 2001-08-16 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
US6835838B2 (en) | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
MXPA04007396A (en) * | 2002-01-31 | 2004-10-11 | Novartis Ag | Process for the manufacture of hmg-coa reductase inhibitors. |
GB0204129D0 (en) | 2002-02-21 | 2002-04-10 | Novartis Ag | Process for the manufacture of organic compounds |
US20050130978A1 (en) | 2002-04-17 | 2005-06-16 | Masamichi Yuda | Novel crystal of quinoxalinedione derivative anhydride |
GB0210234D0 (en) | 2002-05-03 | 2002-06-12 | Novartis Ag | Process for the manufacture of organic compounds |
TWI328006B (en) | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
CN100344422C (en) * | 2006-05-11 | 2007-10-24 | 朱能国 | Method for manufacturing flame-retardant moisture-proof decoration panel by planted pine and its slab |
JP5353678B2 (en) * | 2009-12-17 | 2013-11-27 | トヨタ自動車株式会社 | Vehicle control device |
-
2004
- 2004-02-02 PL PL376557A patent/PL376557A1/en unknown
- 2004-02-02 CN CN201110189197.4A patent/CN102285916B/en not_active Expired - Lifetime
- 2004-02-02 JP JP2006501997A patent/JP5192147B2/en not_active Expired - Lifetime
- 2004-02-02 EP EP12001247A patent/EP2500339A1/en not_active Withdrawn
- 2004-02-02 CA CA002513837A patent/CA2513837A1/en not_active Abandoned
- 2004-02-02 US US10/544,752 patent/US20060142582A1/en not_active Abandoned
- 2004-02-02 EP EP04707232A patent/EP1592668A1/en not_active Withdrawn
- 2004-02-02 CN CN2008100012910A patent/CN101219992B/en not_active Expired - Lifetime
- 2004-02-02 WO PCT/EP2004/050066 patent/WO2004072040A1/en active Application Filing
- 2004-02-02 EP EP17200172.9A patent/EP3299359A1/en not_active Withdrawn
- 2004-02-02 CN CNB2004800039523A patent/CN100374422C/en not_active Expired - Lifetime
- 2004-02-02 AU AU2004212160A patent/AU2004212160B2/en not_active Expired
- 2004-02-02 DE DE202004021379U patent/DE202004021379U1/en not_active Expired - Lifetime
- 2004-02-02 CA CA2785954A patent/CA2785954A1/en not_active Abandoned
- 2004-02-10 TW TW102126646A patent/TWI485135B/en not_active IP Right Cessation
- 2004-02-10 TW TW100127719A patent/TW201213311A/en unknown
- 2004-02-10 TW TW103129170A patent/TW201514149A/en unknown
- 2004-02-10 TW TW093103012A patent/TW200420541A/en unknown
-
2008
- 2008-12-09 US US12/331,086 patent/US20090182008A1/en not_active Abandoned
-
2011
- 2011-06-07 JP JP2011127696A patent/JP2011201915A/en not_active Withdrawn
- 2011-10-25 US US13/280,431 patent/US20120101126A1/en not_active Abandoned
-
2012
- 2012-10-31 US US13/664,498 patent/US8557993B2/en not_active Expired - Lifetime
-
2013
- 2013-06-25 JP JP2013132593A patent/JP5366163B2/en not_active Expired - Lifetime
- 2013-09-03 US US14/016,399 patent/US8853405B2/en not_active Expired - Lifetime
- 2013-09-03 JP JP2013182394A patent/JP5445713B2/en not_active Expired - Lifetime
- 2013-12-06 JP JP2013253095A patent/JP5500305B2/en not_active Expired - Lifetime
- 2013-12-20 JP JP2013264348A patent/JP2014055185A/en not_active Withdrawn
-
2014
- 2014-07-30 JP JP2014155001A patent/JP5702494B2/en not_active Expired - Lifetime
- 2014-08-05 JP JP2014159459A patent/JP2014205723A/en not_active Withdrawn
- 2014-08-26 US US14/468,572 patent/US20140364614A1/en not_active Abandoned
-
2015
- 2015-07-06 JP JP2015135320A patent/JP2015172086A/en not_active Withdrawn
- 2015-10-01 US US14/872,255 patent/US20160024010A1/en not_active Abandoned
-
2016
- 2016-10-04 US US15/284,561 patent/US20170022163A1/en not_active Abandoned
- 2016-10-05 JP JP2016197459A patent/JP2016222737A/en not_active Withdrawn
-
2017
- 2017-10-05 US US15/725,397 patent/US20180029987A1/en not_active Abandoned
- 2017-12-20 JP JP2017244040A patent/JP2018044009A/en not_active Withdrawn
-
2018
- 2018-08-03 US US16/053,879 patent/US20180346425A1/en not_active Abandoned
- 2018-11-29 JP JP2018223591A patent/JP2019031574A/en active Pending
-
2019
- 2019-05-01 US US16/400,566 patent/US20190256469A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/740,516 patent/US20200148644A1/en not_active Abandoned
- 2020-06-30 JP JP2020113164A patent/JP2020169196A/en active Pending
- 2020-09-23 US US17/029,692 patent/US20210002227A1/en not_active Abandoned
-
2022
- 2022-02-18 US US17/675,413 patent/US20220169614A1/en not_active Abandoned
-
2023
- 2023-06-16 US US18/336,332 patent/US20230322680A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557993B2 (en) * | 2003-02-12 | 2013-10-15 | Nissan Chemical Industries Ltd. | Crystalline forms of pitavastatin calcium |
US8853405B2 (en) * | 2003-02-12 | 2014-10-07 | Nissan Chemical Industries Ltd. | Crystalline forms of pitavastatin calcium |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230322680A1 (en) | Crystalline forms of pitavastatin calcium | |
US7777049B2 (en) | Crystalline forms of Rizatriptan benzoate | |
Schoening | Van der Schaaf et al. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |